Get Ready For the Great Wall Street Divide

Fellow Investor,

This will be one of the most interesting earnings seasons I’ve ever seen in my 33 years of covering the markets.

The results will divide Wall Street in half again.

On one side, many companies that delivered triple-digit earnings surprises last quarter will miss their numbers terribly and their stock prices will collapse.

On the other side, a new set of small companies in overlooked sectors will explode with triple-digit earnings and monster earnings surprises.

As a result, their stock prices should not only jump 30% to 50% on the news but double soon after that.

My No. 1 recommendation is in that second category that jumps 30% to 50% on earnings. In fact, this biotech juggernaut has already handed my readers 392% profits in 19 months!

This is your opportunity to grab it before it doubles my readers’ money again—Free—but only for the next 24 hours and for reasons I will explain in a moment.

But first…

What makes this stock another sure double?

Let me explain…

The greatest biotech revolution the world has ever seen has triggered a mad dash by institutional investors, money managers, and broker houses into a number of developmental-stage biotechnology companies.

It’s no wonder: Recent advances in genetics, DNA screening, gene therapy, tissue engineering, and printable organs show that we may be just months away from cures that were once unthinkable.

      • Cures for cancer…
      • Cures for heart disease…
      • Cures for Alzheimer’s …
      • Cures for diabetes…
      • Cures for rare genetic diseases
      • And cures for many, many more terrible illnesses…

The chain reaction is about to hand my Emerging Growth readers ANOTHER 100% profit in this top biotech play in the next 90 days.

The reason is simple:

Our research shows the company’s treatments for colitis, angioedema, and travelers’ diarrhea could triple—that’s right, triple—the company’s 2012 revenue.

How can this be?

      1. On January 14, 2013, the FDA approved its colitis treatment—pushing share prices 11% higher.
      2. In the five months since the company’s colitis treatment was launched, the company has seen sales jump $22 million. With such a fast start we expect revenues to double again by year’s end.
      3. What’s more, the company’s new acid reflux product has one key advantage over its competitors: It offers the longest lasting acid control in the market—nearly 19 hours. The results will drive millions more in annual sales and earnings, not just for the next 90 days but for years to come.
      4. In addition, the company’s anti-diabetes agent just received a huge endorsement from the AACE (American Academy of Clinical Endocrinologists), whose guidelines doctors use in prescribing. With the annual diabetes market estimated at $35 billion, that’s like winning a $100 million lottery every year as tens of thousands of doctors begin to prescribe this company’s new treatments over the competition.
      5. As if that weren’t exciting enough, the company’s angioedema treatment just received orphan drug status from the FDA. As a result, the company will now receive a windfall in tax incentives, plus enhanced patented production and marketing rights—not to mention subsidies for its clinical research.

This is why the company’s stock price has soared 392% since I first recommended it in March 2012. With the analyst community expecting the company to declare another 150% earnings growth come November, we see the upward trajectory on this stock continuing for some time to come.

This is also why, if you can add this one to your holdings before it declares earnings—and before the pension funds pile in—you could easily grab its next 100% gain by the end of the year.

Because the opportunity is so great here, I want to give you the full details on this profitable recommendation, along with a 90-day risk-free trial to my Emerging Growth advisory, so you can get a taste of the kinds of profits you will make when you invest alongside us, without risking a dime.

Here are a few more exciting details to whet your appetite:

Over the past 12 months, the company…

      • Has registered 89% sales growth and 2,032% earnings growth year over year,
      • Has analysts forecasting another 154% earnings rise come November 4 when it reports earnings,
      • Has a forward P/E ratio of—get this—just 15, and that’s after the stock has handed my readers 395% gains in 19 months,
      • Has a market cap of under $2 billion,
      • Has one of the strongest buy ratings of any of our stocks, and
      • Has just reported a 7.8% sales surprise and 72.2% earnings surprise and doubled its full-year outlook from $0.72 to $0.81 per share to $1.61 to $1.65 per share.

Which is why the company is about to clobber Wall Street and double investors’ money again.

In fact, no other recommendation on our Buy List has stronger buy ratings both fundamentally AND technically, with “A” rankings across ALL of our 10 proven profitable measurements.

That’s why I want to send you my complete recommendation here, including my in-depth analysis and buy below and target prices—all 100% risk-free of charge.

And not just for my No. 1 recommendation, my friend, but for all of them.

Why am I doing this?

Because it’s the best way I know for you to preview my Emerging Growth service without risking a dime.

Look…

If our small stocks perform as we expect them to this earnings season, I will have won you as a reader for life. If not, you will have risked nothing.

That’s why I’ve made it possible for you to receive all of my current recommendations risk-free for the next 90 days—with no obligation beyond those 90 days if you’re not 100% thrilled with your results.

In other words, the risk is all mine and the profits are all yours.

So for simply accepting my risk-free offer today…

You’ll get the name of my No. 1 recommendation along with complete access to every one of my current Buy List recommendations, my archive of past issues and economic reports, my stock ranking system, and message boards where we can communicate one-on-one for a full 90 days without you risking a penny.

You’ll also receive Risk-FREE Access to my $9-to-$1 Market beating Emerging Growth Advisory for 90 days

When you consider my offer also includes my one-day discount, you’ll agree, it doesn’t get any better than this.

So if you’ve always wanted to test-drive my $9-to-$1 market-beating service 100% RISK-FREE, and lock in my lowest price for the next 90 days, now is the time, as I simply can’t tell you that I will find an equally profitable opportunity when 3th quarter earnings season begins in October.

Since 1980, I’ve helped investors double their money 32 times, by spotting the big earnings trends early, selecting the right stocks, and grabbing them before they break out.

Those who have accepted my previous 90-day risk-free trial offers to test-drive my advisory during earnings season have been richly rewarded with some amazing gains over the years, including:

    • Envirodyne +1,704%
    • Optical Coatings +1,579%
    • L.A. Gear +820%
    • 4Kids Entertainment +786%
    • Photon Dynamics +971%
    • Glenayre Technologies +688%
    • Holly Corporation +457%
    • Hansen Natural +1,125%
    • America Movil +347%
    • Valero +180%
    • Nutrisystem +169%
    • IPSCO +107%
    • Tenaris +98%

We think our newest recommendations will be equally profitable. That’s why I have no problem offering you my services 100% risk-free for the next 90 days, and special savings offer.

That way, you can see for yourself and on your own terms if my Emerging Growth service is right for you.

There is, however, one catch you need to know about:

This special offer to get my No. 1 recommendation, special discount and full advisory benefits RISK-FREE for the next 90 days is good only for the next 24 hours.

You see, once this buy alert becomes public, hedge fund and institutional investors could drive up the price 20%, 30%, even 50% in 24 hours, as they often do—especially when they see my in-depth analysis and complete profit projection.

That’s why this offer ends in 24 hours.

So if you want to get in on this one before Wall Street bids it higher—and test-drive Emerging Growth RISK-FREE for the next 90 days—now is the time to join us.

Click here now to get the name of my No. 1 recommendation and my complete Buy List, and to begin your 90-day RISK-FREE trial.

Sincerely,

Louis Navellier

Louis Navellier

Editor, Emerging Growth

Beating the Market $9-to-$1 since 2003

P.S. Seriously…

…how many stocks can you name that have expanded their profit margins 2,031% or whose stock prices have risen 392% in the past 19 months, or that are set to repeat these numbers on earnings?

This is what makes my No. 1 recommendation the perfect introductory stock pick for you to test-drive my Emerging Growth service for the next 90 days risk-free—without risking a dime.

Again, by simply saying “yes,” you’ll get complete access to every single one of my Buy List recommendations, my archive of past issues and economic reports, my stock rating system, my earnings center, and message boards where we can communicate one-on-one for a full 90 days risk-free.

Act now. My risk-free special savings offer ends at midnight.

More Louis Navellier

Twitter

Facebook

RSS Feed

Little Book

InvestorPlace Network

InvestorPlace.com